uri icon
  • Contact Info
  • +91-22-24127096
Publications in VIVO
 

Singh, Meenakshi Transfusion Medicine

Positions

  • Scientific Officer, TMH

 I was awarded doctorate by All India Institute of Medical Sciences (A.I.I.M.S.) in 2004 in the field of Immunology and Immunogenetics. Post doctorate, I have pursued research in the field of bone marrow and renal transplantation under the aegis of Dept. Of Transplant Immunology & Immunogentics, AIIMS. The main thrust of my doctorate studies has been on ‘MHC and infection’ with special emphasis on Leprosy. I have investigated the critical peptide residues required for allele–specific binding to MHC molecules. This has led to the identification of pockets within the peptide binding cleft involved in various forms of clinical leprosy. Further, we correlated the genetic profiles of the patients with functional profiles in the form of effector T-cell differentiation markers. By using high throughput DNA typing methods for defining HLA alleles in these patients, we obtained data on MHC restriction pattern of immune responsiveness in M. leprae infections. Subsequently, the role of non MHC genes that might influence susceptibility to leprosy was investigated in collaboration with the Center for host resistance, McGill University, Canada. The work has been published in journals such as Nature Genetics, Tissue Antigens, Transplantation, etc and has been highly cited. The impact factor of these journals ranges from 4 to 36. During post doctorate I worked on patient specific pharmacogenetic and hepatotoxicity prognosis in anti-tubercular treatment. We hypothesized that the ATT-hepatotoxicity may be a result of single nucleotide polymorphisms (SNPs) in the drug metabolizing enzymes (DME). In turn the relative activity and abundance of DME is the effect of genetic variations in promoter regions and nuclear receptors. The results may be useful to the clinician to screen patients who are at a higher risk of developing ATT-hepatotoxicity. The work may also pave the way for individualized dose sizing based on the interindividual genotypes.